8 JULY - FDA will soon publish a Federal Register notice extending the period for public comment on how the agency's regulation of commercial speech can best safeguard public health while complying with First Amendment protections.
FDA will soon publish aFederal Register notice extending the period for public commenton how the agency's regulation of commercial speech can bestsafeguard public health while complying with First Amendmentprotections.http://www.fda.gov/bbs/topics/NEWS/2002/NEW00819.html
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Article
COMMENT PERIOD EXTENDED FOR PUBLIC DISCUSSION OF FDA AND 1ST AMENDMENT
Author(s):
8 JULY - FDA will soon publish a Federal Register notice extending the period for public comment on how the agency's regulation of commercial speech can best safeguard public health while complying with First Amendment protections.
FDA will soon publish aFederal Register notice extending the period for public commenton how the agency's regulation of commercial speech can bestsafeguard public health while complying with First Amendmentprotections.http://www.fda.gov/bbs/topics/NEWS/2002/NEW00819.html
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Nxera and Cancer Research UK Advance Oral EP4 Antagonist into Phase IIa Study
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
CSL Backs Late-Stage Development of VarmX’s Coagulation Therapy VMX-C001X
Mastering Antibody-Drug Conjugates
Limula’s LimONE System Targets Consistency in Stem Cell Transplants
Gyala Therapeutics’ CAR-T Leukemia Therapy Shows Promise, Heads for Clinical Trial
Nxera and Cancer Research UK Advance Oral EP4 Antagonist into Phase IIa Study
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
CSL Backs Late-Stage Development of VarmX’s Coagulation Therapy VMX-C001X
Mastering Antibody-Drug Conjugates
Limula’s LimONE System Targets Consistency in Stem Cell Transplants
Gyala Therapeutics’ CAR-T Leukemia Therapy Shows Promise, Heads for Clinical Trial